Home » Stocks » LNTH

Lantheus Holdings, Inc. (LNTH)

Stock Price: $13.17 USD 0.17 (1.31%)
Updated November 27, 1:00 PM EST - Market closed
After-hours: $12.89 -0.28 (-2.13%) Nov 27, 2:47 PM

Stock Price Chart

Key Info

Market Cap 880.70M
Revenue (ttm) 334.60M
Net Income (ttm) 389,000
Shares Out 66.87M
EPS (ttm) 0.01
PE Ratio 1,317.00
Forward PE 28.90
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $13.17
Previous Close $13.00
Change ($) 0.17
Change (%) 1.31%
Day's Open 13.07
Day's Range 12.97 - 13.21
Day's Volume 97,926
52-Week Range 8.67 - 21.42

More Stats

Market Cap 880.70M
Enterprise Value 1.02B
Earnings Date (est) Jan 1, 1970
Ex-Dividend Date n/a
Shares Outstanding 66.87M
Float n/a
EPS (basic) 0.08
EPS (diluted) 0.01
FCF / Share 0.37
Dividend n/a
Dividend Yield n/a
Earnings Yield 0.08%
FCF Yield 2.82%
Payout Ratio n/a
Shares Short 2.02M
Short Ratio 3.70
Short % of Float n/a
Beta 1.30
PE Ratio 1,317.00
Forward PE 28.90
P/FCF Ratio 35.49
PS Ratio 2.63
PB Ratio 1.71
Revenue 334.60M
Operating Income 8.77M
Net Income 389,000
Free Cash Flow 24.82M
Net Cash -134.81M
Net Cash / Share -2.02
Gross Margin 52.24%
Operating Margin 2.62%
Profit Margin 0.10%
FCF Margin 7.42%
ROA 2.59%
ROE 0.13%
ROIC 0.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (3)

Buy 2
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$19.33*
(46.77% upside)
Low
16.0
Current: $13.17
High
22.0
Target: 19.33
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018201720162015201420132012
Revenue347343331302293302284288
Revenue Growth1.15%3.62%9.78%2.86%-2.7%6.32%-1.54%-
Gross Profit17517516213813612677.3675.20
Operating Income51.6664.4951.8556.5942.5339.42-18.89-0.75
Net Income31.6740.5212326.76-14.75-3.56-61.56-42.00
Shares Outstanding38.9938.2337.2832.0424.4418.0818.03-
Earnings Per Share0.791.033.170.82-0.60-0.20-3.42-0.84
EPS Growth-23.3%-67.51%286.59%-----
Operating Cash Flow80.3861.1954.7849.6421.7611.59-15.57-0.37
Capital Expenditures-22.06-19.13-16.313.21-13.15-7.91-3.48-7.92
Free Cash Flow58.3242.0638.4752.858.613.68-19.06-8.29
Cash & Equivalents92.9211376.2951.1828.6019.7418.58-
Total Debt194266268278354401407-
Net Cash / Debt-101-153-192-227-325-381-388-
Assets406440384256242243261-
Liabilities291369361362428482497-
Book Value11571.0023.29-107-185-239-236-
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Lantheus Holdings, Inc.
Country United States
Employees 508
CEO Mary Anne Heino

Stock Information

Ticker Symbol LNTH
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: LNTH
IPO Date June 25, 2015

Description

Lantheus Holdings develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine. The company also offers Xenon, a radiopharmaceutical gas used to assess pulmonary function, and to image cerebral blood flow; Neurolite, an injectable to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable technetium-labeled imaging agent; FDG, a fluorine-18-radiolabeled imaging agent to identify and characterize tumors in patients undergoing oncologic diagnostic procedures; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In addition, it provides injectable radiopharmaceutical imaging agents, such as Thallium TI 201, which is used in MPI studies to detect cardiovascular disease; Gallium Ga 67 that is used to detect various infections and cancerous tumors; and Quadramet, a therapeutic product. Further, the company is developing Flurpiridaz F 18, which is in Phase III clinical trials to assess blood flow to the heart; and LMI 1195 that is in Phase III clinical trials for the diagnosis and treatment of neuroendocrine tumors. It sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics, and group practices. The company has a strategic collaboration and license agreement with NanoMab Technology Limited to provide an imaging biomarker research tool to pharmaceutical companies and academic centers conducting R&D on PD-L1 immuno-oncology treatments; and strategic collaboration with Insightec Ltd. for the treatment of glioblastoma and neurodegenerative conditions. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.